|Bid||0.0000 x 800|
|Ask||0.0000 x 2900|
|Day's range||3.3800 - 3.7000|
|52-week range||3.3800 - 8.4380|
|Beta (5Y monthly)||1.32|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||16.47|
Here is how CNS Pharmaceuticals, Inc. (CNSP) and Celyad SA (CYAD) have performed compared to their sector so far this year.
MONT-SAINT-GUIBERT, Belgium, January 10, 2022--Regulatory News: Celyad Oncology SA (Euronext & Nasdaq: CYAD) (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced a 2021 year-end review and provided an outlook for 2022.
Biotech stocks from the Medical sector, including APTO, CELU, CNSP, CYAD and SPRB, might be witnessing a turnaround in 2022 to emerge as solid investment options.